New technical developments are making it increasingly cost-effective to provide newborn screening for increased numbers of rare genetic disorders (see previous news), and many countries are expanding their programmes with conditions relevant to their populations. The difficulty is sometimes in determining whether early diagnosis is beneficial – if there is no clear clinical advantage, is it still worthwhile in preventing unnecessary clinical investigations, and to inform parental reproductive choices? 

comments powered by Disqus